Skip to content
stoqly

Mettler Toledo

MTD NYSE Life Sciences Tools & Services Financials FY2016–FY2025

Mettler Toledo's revenue rose 4.0% to $4.0 billion in fiscal 2025. Its net margin was 21.6%, down from 22.3% a year earlier. Free cash flow was $849 million, down 1.8%. It paid out $800 million in dividends and buybacks, 94% of free cash flow. The diluted share count fell 3.0%.

Last close · Oct 23, 2026

$1,670.29

0.9%
Value it Compare
Revenue Total sales reported in the income statement.
$4.0B
4.0% vs prior year
Operating margin Operating income as a share of revenue.
—
Net income Profit after all expenses, interest and tax.
$869M
0.7%
Free cash flow Cash from operations minus capital spending.
$849M
1.8%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
50.5%
5.2 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$33.7B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
37.6x
On $44.38 EPS (TTM)

What Mettler Toledo does

No business description yet.

Legal name
Mettler-Toledo International Inc.
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001037646-26-000011
0001037646

Revenue and margins

Mettler Toledo had $4.0B of revenue in fiscal 2025, up 4.0% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2016 to 2025, diluted EPS grew 12.8% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $849M in fiscal 2025, 21.1% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Mettler Toledo returned $800M to shareholders in fiscal 2025, 94% of free cash flow. The diluted share count fell 3.0%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Mettler Toledo yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$2.0B and divides by 20.7M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 37.6x · peers 48.3x · sector 27.9x.

Balance sheet

Cash, debt and the ratios that show how comfortably Mettler Toledo can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $98.6M$96.0M$69.8M$59.4M$66.9M
Debt incl. finance leases $1.6B$1.9B$1.9B$1.8B$2.1B
Net debt / EBITDA 1.4x1.5x1.6x1.5x1.7x
Debt / equity 9.2x————
Interest coverage 23.0x20.3x13.6x14.9x16.3x
Current ratio 1.1x1.2x1.0x1.0x1.1x
Quick ratio 0.8x0.8x0.7x0.7x0.8x
Total assets $3.3B$3.5B$3.4B$3.2B$3.7B
Total liabilities $3.2B$3.5B$3.5B$3.4B$3.7B
Shareholders' equity $171M$24.8M−$150M−$127M−$23.6M
Net debt (− = net cash) $1.5B$1.8B$1.8B$1.8B$2.0B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$32.5M

5 insiders

Of sales under plans

0%

$0.0M

DateInsiderTradeSharesPriceValueFiling
Aug 27, 2026 Patrick KaltenbachPresident and CEO Sold 942 $1,425.00 $1.3M Form 4
Aug 5, 2026 Thomas P SaliceDirector Sold 417 $1,440.41 $0.6M Form 4
Aug 3, 2026 Gerry KellerHead of Process Analytics Sold 240 $1,427.14 $0.3M Form 4
Aug 3, 2026 Shawn VadalaChief Financial Officer Sold 2,240 $1,432.00 $3.2M Form 4
Aug 3, 2026 Thomas P SaliceDirector Sold 415 $1,444.62 $0.6M Form 4
Feb 10, 2026 Shawn VadalaChief Financial Officer Sold 800 $1,410.12 $1.1M Form 4
Nov 25, 2025 la Guerroniere Marc deHead of Eur & NA Market Orgs Sold 6,055 $1,488.18 $9.0M Form 4
Nov 25, 2025 Shawn VadalaChief Financial Officer Sold 1,000 $1,511.00 $1.5M Form 4
Nov 24, 2025 Shawn VadalaChief Financial Officer Sold 1,025 $1,452.00 $1.5M Form 4
Nov 21, 2025 Gerry KellerHead of Process Analytics Sold 236 $1,418.58 $0.3M Form 4
Nov 12, 2025 Patrick KaltenbachPresident and CEO Sold 2,000 $1,462.50 $2.9M Form 4
Nov 11, 2025 la Guerroniere Marc deHead of Eur & NA Market Orgs Sold 6,880 $1,450.00 $10.0M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✕ ✓ ✓
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✓ ✕ ✕
Current ratio rose ✕ ✕ ✓
Share count didn't rise ✓ ✓ ✓
Gross margin rose ✓ ✓ ✕
Revenue rose relative to assets ✕ ✓ ✓
F-score 6 / 97 / 97 / 9
Accruals ratio −5.2%−3.2%−2.5%
Altman Z'' 9.4510.7410.42

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Mettler Toledo MTD $33.7B 4.0% — 21.1% 50.5% 37.6x 7
Charles River Laboratories CRL $16.6B −0.9% 0.6% 12.9% 0.4% — 4 Compare →
Illumina ILMN $41.2B −0.7% 18.6% 21.4% 20.3% 50.3x 8 Compare →
Waters WAT $44.6B 7.0% 25.4% 17.1% 21.0% — 6 Compare →
Bio-Rad Laboratories BIO $9.9B 0.7% 1.8% 14.5% 0.5% 46.3x 5 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $2.5B $2.7B $2.9B $3.0B $3.1B $3.7B $3.9B $3.8B $3.9B $4.0B
Gross profit $1.4B $1.6B $1.7B $1.7B $1.8B $2.2B $2.3B $2.2B $2.3B $2.4B
Research and development $119M $128M $141M $144M $140M $170M $177M $185M $189M $199M
Interest expense $28.0M $32.8M $34.5M $37.4M $38.6M $43.2M $55.4M $77.4M $74.6M $68.5M
Pretax income $504M $574M $652M $681M $749M $949M $1.1B $974M $1.0B $1.0B
Income tax $120M $198M $139M $120M $146M $180M $198M $185M $174M $180M
Net income $384M $376M $513M $561M $603M $769M $873M $789M $863M $869M
Diluted EPS $14.22 $14.24 $19.88 $22.47 $24.91 $32.78 $38.41 $35.90 $40.48 $42.05
Diluted shares 0.03B 0.03B 0.03B 0.03B 0.02B 0.02B 0.02B 0.02B 0.02B 0.02B
Cash flow
Cash from operations $461M $516M $565M $603M $725M $909M $859M $966M $968M $956M
Capital expenditure $124M $127M $143M $97.3M $92.5M $108M $121M $105M $104M $107M
Free cash flow $337M $389M $422M $506M $632M $801M $738M $861M $864M $849M
Depreciation and amortization $41.0M $45.0M $51.5M $54.1M $57.7M $67.5M $73.3M $76.6M $77.5M $79.6M
Stock-based compensation $15.3M $16.6M $17.6M $18.3M $18.7M $19.6M $19.7M $17.9M $20.0M $22.5M
Acquisitions $111M $108M $5.5M $2.0M $6.2M $221M $38.0M $5.8M $10.1M $93.8M
Share buybacks $500M $400M $475M $775M $775M $1.0B $1.1B $900M $850M $800M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $500M $400M $475M $775M $775M $1.0B $1.1B $900M $850M $800M
Balance sheet
Cash and short-term investments $159M $149M $178M $208M $94.3M $98.6M $96.0M $69.8M $59.4M $66.9M
Total debt $875M $960M $985M $1.2B $1.3B $1.6B $1.9B $1.9B $1.8B $2.1B
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $6.2M $16.3M
Current assets $897M $1.0B $1.0B $1.1B $1.1B $1.3B $1.4B $1.2B $1.2B $1.4B
Current liabilities $588M $690M $734M $755M $840M $1.1B $1.1B $1.2B $1.2B $1.2B
Inventory $222M $255M $269M $274M $298M $415M $442M $386M $342M $387M
Property and equipment, net $564M $668M $718M $749M $799M $799M $779M $803M $770M $846M
Total assets $2.2B $2.5B $2.6B $2.8B $2.8B $3.3B $3.5B $3.4B $3.2B $3.7B
Total liabilities $1.7B $2.0B $2.0B $2.4B $2.5B $3.2B $3.5B $3.5B $3.4B $3.7B
Shareholders' equity $435M $547M $590M $421M $283M $171M $24.8M −$150M −$127M −$23.6M
Margins
Gross margin 57.3% 57.8% 57.4% 57.9% 58.4% 58.4% 58.9% 59.2% 60.1% 59.4%
EBITDA margin 22.9% 23.9% 25.1% 25.7% 27.4% 28.5% 30.6% 29.8% 30.7% 29.7%
Net margin 15.3% 13.8% 17.5% 18.7% 19.5% 20.7% 22.3% 20.8% 22.3% 21.6%
FCF margin 13.4% 14.3% 14.4% 16.8% 20.5% 21.6% 18.8% 22.7% 22.3% 21.1%
Returns
Return on capital 36.8% 31.7% 39.2% 41.6% 43.4% 51.4% 52.6% 48.6% 55.7% 50.5%
Return on capital employed 35.7% 35.3% 36.7% 36.7% 39.3% 47.8% 49.8% 46.5% 52.4% 48.7%
Return on equity 75.7% 76.6% 90.1% 111.0% 171.4% 338.7% — — — —
Return on assets 18.6% 15.9% 19.8% 20.8% 21.5% 25.0% 25.6% 23.0% 26.2% 25.0%
Growth
Revenue growth 4.7% 8.6% 7.7% 2.5% 2.5% 20.5% 5.4% −3.4% 2.2% 4.0%
Net income growth 8.9% −2.2% 36.3% 9.5% 7.4% 27.6% 13.5% −9.6% 9.4% 0.7%
EPS growth 13.9% 0.1% 39.6% 13.0% 10.9% 31.6% 17.2% −6.5% 12.8% 3.9%
FCF growth −5.7% 15.5% 8.6% 19.9% 24.9% 26.7% −7.9% 16.6% 0.5% −1.8%
Share count change −4.4% −2.3% −2.3% −3.1% −3.1% −3.1% −3.2% −3.3% −3.0% −3.0%
Financial health
Net debt / EBITDA 1.3x 1.2x 1.1x 1.3x 1.4x 1.4x 1.5x 1.6x 1.5x 1.7x
Debt / equity 2.0x 1.8x 1.7x 2.9x 4.5x 9.2x — — — —
Interest coverage 19.0x 18.5x 19.9x 19.2x 20.4x 23.0x 20.3x 13.6x 14.9x 16.3x
Current ratio 1.5x 1.5x 1.4x 1.5x 1.3x 1.1x 1.2x 1.0x 1.0x 1.1x
Quick ratio 1.2x 1.1x 1.1x 1.1x 0.9x 0.8x 0.8x 0.7x 0.7x 0.8x
Capital allocation
Capex / revenue 4.9% 4.7% 4.9% 3.2% 3.0% 2.9% 3.1% 2.8% 2.7% 2.7%
Stock comp / revenue 0.6% 0.6% 0.6% 0.6% 0.6% 0.5% 0.5% 0.5% 0.5% 0.6%
Payouts / FCF 148.5% 102.9% 112.5% 153.1% 122.6% 124.8% 149.1% 104.6% 98.3% 94.3%
Quality scores
Piotroski F-score 8.0 6.0 6.0 7.0 6.0 7.0 5.0 6.0 7.0 7.0
Altman Z'' 7.5 7.1 7.8 8.0 8.4 8.1 8.9 9.5 10.7 10.4
Accruals ratio −3.7% −6.0% −2.0% −1.6% −4.4% −4.6% 0.4% −5.2% −3.2% −2.5%

Source: SEC EDGAR XBRL filings (CIK 0001037646). Data updated October 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open